These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1211 related items for PubMed ID: 16014534
41. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases. Salonen EM, Miettinen A, Walle TK, Koskenmies S, Kere J, Julkunen H. Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381 [Abstract] [Full Text] [Related]
42. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics. van Vollenhoven RF, Bieber MM, Powell MJ, Gupta PK, Bhat NM, Richards KL, Albano SA, Teng NN. J Rheumatol; 1999 Aug; 26(8):1727-33. PubMed ID: 10451069 [Abstract] [Full Text] [Related]
43. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Julkunen H, Ekblom-Kullberg S, Miettinen A. Rheumatol Int; 2012 Aug; 32(8):2445-51. PubMed ID: 21706294 [Abstract] [Full Text] [Related]
44. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Jaekell HP, Trabandt A, Grobe N, Werle E. Lupus; 2006 Aug; 15(6):335-45. PubMed ID: 16830879 [Abstract] [Full Text] [Related]
45. Negative anti-C1q antibody titers may influence therapeutic decisions and reduce the number of renal biopsies in systemic lupus erythematosus. Moura CG, Mangueira CL, Cruz LA, Cruz CM. Nephron Clin Pract; 2011 Aug; 118(4):c355-60. PubMed ID: 21325866 [Abstract] [Full Text] [Related]
46. Relevance of anti-C1q autoantibodies to lupus nephritis. Tsirogianni A, Pipi E, Soufleros K. Ann N Y Acad Sci; 2009 Sep; 1173():243-51. PubMed ID: 19758158 [Abstract] [Full Text] [Related]
47. [Is autoantibody determination in patients with systemic lupus erythematosus useful? Anti-C1q-autoantibody as an example]. Trendelenburg M, Schifferli JA. Praxis (Bern 1994); 1998 Dec 24; 87(51-52):1811-3. PubMed ID: 10025155 [Abstract] [Full Text] [Related]
48. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Magalhães MB, da Silva LM, Voltarelli JC, Donadi EA, Louzada-Junior P. Scand J Rheumatol; 2007 Dec 24; 36(6):442-7. PubMed ID: 18092265 [Abstract] [Full Text] [Related]
49. Anti-C1q antibodies in lupus nephritis and their correlation with the disease activity. Emad G, Al-Barshomy SM. Saudi J Kidney Dis Transpl; 2020 Dec 24; 31(2):342-352. PubMed ID: 32394906 [Abstract] [Full Text] [Related]
50. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus. Hanly JG, Thompson K, McCurdy G, Fougere L, Theriault C, Wilton K. J Immunol Methods; 2010 Jan 31; 352(1-2):147-52. PubMed ID: 19836394 [Abstract] [Full Text] [Related]
51. Anti-dsDNA, anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus. Zivković V, Stanković A, Cvetković T, Mitić B, Kostić S, Nedović J, Stamenković B. Srp Arh Celok Lek; 2014 Jan 31; 142(7-8):431-6. PubMed ID: 25233687 [Abstract] [Full Text] [Related]
52. Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. Sjoholm AG, Martensson U, Sturfelt G. J Rheumatol; 1997 May 31; 24(5):871-8. PubMed ID: 9150075 [Abstract] [Full Text] [Related]
53. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Jönsson G, Sjöholm AG, Truedsson L, Bengtsson AA, Braconier JH, Sturfelt G. Rheumatology (Oxford); 2007 Jul 31; 46(7):1133-9. PubMed ID: 17478473 [Abstract] [Full Text] [Related]
54. Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis. Heidenreich U, Mayer G, Herold M, Klotz W, Stempfl Al-Jazrawi K, Lhotta K. Lupus; 2009 Dec 31; 18(14):1276-80. PubMed ID: 19854810 [Abstract] [Full Text] [Related]
55. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Tsacheva I, Radanova M, Todorova N, Argirova T, Kishore U. Mol Immunol; 2007 Mar 31; 44(8):2147-51. PubMed ID: 17049989 [Abstract] [Full Text] [Related]
56. Correlation between the renal C1q deposition and serum anti-C1q antibody: a potential role of anti-C1q antibody in lupus nephritis. Chen PC, Wang CR, Liu MF, Chen FF, Liang CC. Asian Pac J Allergy Immunol; 2002 Dec 31; 20(4):223-7. PubMed ID: 12744622 [Abstract] [Full Text] [Related]
57. Anti-DNA and anti-nucleosome antibody affinity--a mirror image of lupus nephritis? Williams RC, Malone C, Blood B, Silvestris F. J Rheumatol; 1999 Feb 31; 26(2):331-46. PubMed ID: 9972967 [Abstract] [Full Text] [Related]
58. Autoantibodies in lupus nephritis patients requiring renal transplantation. Stinton LM, Barr SG, Tibbles LA, Yilmaz S, Sar A, Benedikttson H, Fritzler MJ. Lupus; 2007 Feb 31; 16(6):394-400. PubMed ID: 17664229 [Abstract] [Full Text] [Related]
59. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus. Mak A, Cheung BM, Mok CC, Leung R, Lau CS. Rheumatology (Oxford); 2006 Oct 31; 45(10):1266-72. PubMed ID: 16595522 [Abstract] [Full Text] [Related]